Increased expression of lncFOXC1 promotes liver cancer formation

doi:10.12092/j.issn.1009-2501.2019.01.005

Abstract

Abstract:

AIM: To investigate the expression of long noncoding RNA lncFOXC1 in liver cancer and the role in liver cancer formation. METHODS: A total of 34 liver cancer and peri-tumor tissues were collected. Expression of lncFOXC1 was detected by qRT-PCR in liver cancer and peri-tumor tissues, as well as liver cancer cell spheres. LncFOXC1 deficiency cell lines were constructed by shRNA. Then, its roles in sphere formation and in vivo tumor growth assays were studied. RESULTS: lncFOXC1 was significantly highly expressed in liver cancer tissues and liver cancer cell sphere. LncFOXC1 deficiency significantly reduced sphere formation and tumor growth. CONCLUSION: LncFOXC1 is highly expressed in liver cancer tissues, and can regulate liver cancer stem cell growth.

Key words: lncFOXC1, liver cancer, cancer stem cell

CLC Number:

R965.2
R73

ZHOU Yuling, LIU Jiyang, YAO Hongwei, XU Yufen, ZHANG Ting, ZOU Zhuolin, PAN Huan. Increased expression of lncFOXC1 promotes liver cancer formation[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(1): 27-31.

References

［1］Jemal A, Bray F, Center MM, et al. Global cancer statistics［J］. Ca Cancer J Clin, 2011, 61(2):69-90.
［2］Kreso A, Dick JE.Evolution of the cancer stem cell model［J］. Cell Stem Cell, 2014, 14(3):275-291.
［3］Easwaran H,Tsai HC,Baylin SB,et al. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance［J］. Mol Cell, 2014, 54(5):716-727.
［4］Kurtova AV, Xiao J, Mo Q, et al. Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance［J］.Nature, 2015, 517(7533):209-213.
［5］Takebe N, Harris PJ, Warren RQ, et al. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways［J］. Nat Rev Clin Oncol, 2010, 1(2):97.
［6］Gagan J,Van Allen EM.Next-generation sequencing to guide cancer therapy［J］.Gen Med,2015，7(1):80.
［7］Batista PJ, Chang HY. Long noncoding RNAs: Cellular address codes in development and disease［J］. Cell, 2013, 152(6):1298-1307.
［8］Patil DP, Chen CK, Pickering BF, et al. m(6)A RNA methylation promotes XIST-mediated transcriptional repression［J］. Nature, 2016, 537(7620):369.
［9］Leucci E, Vendramin R, Spinazzi M, et al. Melanoma addiction to the long non-coding RNA SAMMSON［J］. Nature, 2016, 531(7595):518-522.
［10］Huarte M. RNA. A lncRNA links genomic variation with celiac disease［J］.Science, 2016, 352(6281):43.
［11］Schmitt AM, Chang HY. Long noncoding RNAs in cancer pathways［J］.Cancer Cell,2016, 29(4):452-463.
［12］Wang Y, Lei H, Ying D, et al. The long noncoding RNA lncTCF7 promotes self-renewal of human liver cancer stem cells through activation of wnt signaling［J］. Cell Stem Cell, 2015, 16(4):413-425.
［13］刘永存, 伍丽萍. STKⅡ在肝癌组织中的表达水平分析及临床意义［J］.空军医学杂志, 2016, 32(5):319-322.
［14］Seok JY, Na DC, Woo HG, et al.A fibrous stromal component in hepatocellular carcinoma reveals a cholangiocarcinoma-like gene expression trait and epithelial-mesenchymal transition［J］. Hepatology, 2012, 55(6):1776-1786.
［15］Engreitz JM, Ollikainen N, Guttman M.Long non-coding RNAs: spatial amplifiers that control nuclear structure and gene expression［J］.Nat Rev Mol Cell Biol, 2016, 17(12):756-770.
［16］Guttman M, Donaghey J, Carey BW, et al. lincRNAs act in the circuitry controlling pluripotency and differentiation［J］. Nature, 2011, 477(7364):295.
［17］Mchugh CA, Chen CK, Chow A, et al.The Xist lncRNA directly interacts with SHARP to silence transcription through HDAC3［J］. Nature, 2015, 521(7551):232-236.
［18］Chu HP, Cifuentes-Rojas C, Kesner B, et al.TERRA RNA Antagonizes ATRX and protects telomeres［J］. Cell, 2017, 170(1):86-101.
［19］Meng L, Ward AJ, Chun S, et al. Towards a therapy for Angelman syndrome by reduction of a long non-coding RNA［J］. Nature, 2015, 518(7539):409-412.
［20］李中文, 吴涛, 付应霄, 等. MicroRNA-31在肝癌中的表达和作用［J］.中国临床药理学与治疗学, 2015,20(10): 1098-1101.
［21］张颖, 周媛凤, 胡敏.肝癌侵袭转移的中医药研究进展［J］.中国临床药理学与治疗学, 2017, 22(5):594-600.

[1]	SHI Dandan, SUN Yiyao, CHEN Xiaoqi, YANG Fangming, ZHANG Chuanlei, WANG Xinting, YUAN Changwei, CHEN Xinju. Curative effect of fuzheng xiaoliu granules in the treatment of primary liver cancer and analysis of serum metabolomics [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1247-1262.
[2]	LIU Yanzhi, WANG Yan, LIU Kaili, ZHOU Wenhua, ZHU Ping, WANG Yingli, DU Shouying. Inhibition and mechanism of Xihuang pill on mice bearing hepatoma H22 tumor [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 754-761.
[3]	LIU Zhuo, TAN Xiaoning, ZENG Puhua. Research progress of glutamine metabolism in liver cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(10): 1159-1166.
[4]	WANG Gaoqing, JIANG Wei, HUA Yongfei. Curative efficacy of retetrexel combined with laparoscopic hepatectomy in treatment of patients with primary liver cancer and its effects on liver function and CIART, AFP-L3 and GP73 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 752-756.
[5]	ZHAO Miaohui, ZHOU Jiani, QI Yong. Mulberry polysaccharides improves the chemotherapy of liver cancer ascites tumor-bearing mice by regulating the PI3K/AKT/mTOR pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 401-407.
[6]	GU Yanling, SHENG Yongjia, WANG Jin. Polysaccharide inhibits tumor associated fibroblasts transformation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 266-271.
[7]	ZHAO Pengcheng, XU Lili, LI Yanling. Effects and safety of target controlled infusion of propofol combined with dexmetomidine in radiofrequency ablation of primary liver cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(6): 682-687.
[8]	SHAN Chang-min, LI Juan, LI Pu. Apoptosis and therapeutic for cells of liver cancers SHAN Chang-min, LI Juan, LI Pu [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(8): 851-856.
[9]	LI Chang-Zheng, WANG Zhi-Qiang, FANG Yi. Inhibition of octreotide on the proliferation of the in vitro cultured liver cancer cell SMMC-7721 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(8): 919-921.